❄️ A Night to Remember: Connecting with the Brightest Minds of Switzerland's Tech Ecosystem❄️ On Monday December 9th, Forestay had the pleasure of co-hosting a warm and engaging pre-event with Swisscom Ventures ahead of EPFL's Investor Day, a cornerstone event for Switzerland's thriving technology ecosystem. The evening was filled with meaningful conversations, inspiring exchanges, and the shared vision of innovation that unites us all. It was an honour to bring together such a dynamic group of individuals – from visionary entrepreneurs to forward-thinking investors – in an atmosphere of collaboration and opportunity. Events like these remind us of the power of human connection and the incredible potential of the Swiss tech scene. We are proud to play our part in fostering innovation and supporting the next generation of ground-breaking ideas through our early-growth investments in the enterprise software ecosystem. Thank you to everyone who joined us for this special evening. We’re excited for the momentum to continue as EPFL’s Investor Day unfolds! 🚀 #Innovation #TechEcosystem #EPFLInvestorDay #Forestay #SwisscomVentures #Collaboration #SwitzerlandTech
Forestay Capital
Wagniskapital- und Private-Equity-Auftraggeber
Genève, Genève 3.216 Follower:innen
Entrepreneurial heritage. Inflection point investing. Shared purpose.
Info
Founded in 2018, Forestay is an early-growth stage tech fund and part of B-FLEXION, an entrepreneurial private investment firm founded by Ernesto Bertarelli. We invest in visionary teams reaching growth inflection points and partner with them to create future category leaders. We support start-ups with investments between $10M and $20M in Europe, Israel and opportunistically on the East coast of the US. Forestay Capital SA is the advisor to Forestay Capital Management Ltd, based in Jersey.
- Website
-
https://www.forestay.vc
Externer Link zu Forestay Capital
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Genève, Genève
- Art
- Privatunternehmen
- Gegründet
- 2018
Orte
-
Primär
Wegbeschreibung
31-33 avenue Giuseppe Motta
Genève, Genève 1202, CH
Beschäftigte von Forestay Capital
Updates
-
💡 Neural Concept to Unveil Real-Time Digital Twin Capabilities at Supercomputing 24 Using NVIDIA Omniverse Blueprint for Real-time Computer-aided Engineering Digital Twins https://lnkd.in/enMb4NGf 🧠 FDA Clears icometrix's icobrain Aria, First AI Tool for Safer ARIA Detection in Alzheimer Treatment https://lnkd.in/ejM8seSf 🤝 Arcitecta and Wasabi Technologies team up to simplify cloud storage https://lnkd.in/eyEM5nPY ⚡ Scandit Releases SDK 7.0: Evolving Smart Data Capture with Intelligence https://lnkd.in/eukefVGA 🏆 K2view Positioned as the Leader in the 2024 SPARK Matrix™ for Data Integration Tools by QKS Group https://lnkd.in/eZ-H7_sd
-
-
Forestay Capital hat dies direkt geteilt
Great milestone today as Mastercard announce Biz360, a business management solution powered by inTandem by vcita. Countless team members on both companies worked extremely hard to get to this day and I would like to thank them all - starting with the great team here at vcita. This project reflect both Mastercard and vcita's commitment to small business digitalization and success, which is the basis for this long term partnership. Exciting times ahead !
Small businesses keep our global economy ticking. That’s why we’re empowering them to manage their operations seamlessly. Meet Mastercard Biz360 – the time-saving solution that enables #smallbusiness owners to cut down on the admin and focus on what matters most. With Biz360, providers will be able to offer their small business customers time-saving tools such as: ➡️ A streamlined digital experience ➡️ Enhanced customer engagement opportunities ➡️ Automation of administrative tasks ➡️ Data-driven insights Explore how Biz360 will transform the digital experience for business owners: https://lnkd.in/eH_vz8xW
-
🌟 Huge congratulations to the icometrix team, who we've backed since 2019, on the FDA clearance of icobrain aria, an important breakthrough in the treatment of Alzheimer’s disease. Icobrain aria is the first and only FDA-cleared medical device for the detection, diagnosis and monitoring of amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new therapies for Alzheimer's disease. This is also a major milestone for the field of neurology, as icobrain aria is the first computer-aided detection (CADe) and diagnosis (CADx) device cleared by the FDA! We are incredibly excited about this groundbreaking achievement, which will undoubtedly have a profound impact on countless lives 🧠 #Alzheimers #ARIA #artificialintelligence #AI #MRI #dementia #neuroradiology #neuroimaging #radiology #neurology #RSNA24
❗️🚨❗️🚨❗️ 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦 I am incredibly excited to announce the FDA clearance of icobrain aria, as the 𝗳𝗶𝗿𝘀𝘁 𝗮𝗻𝗱 𝗼𝗻𝗹𝘆 𝗙𝗗𝗔-𝗰𝗹𝗲𝗮𝗿𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲 for the detection, diagnosis, and monitoring of amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new amyloid-targeting therapies for Alzheimer's disease. This is also a major milestone for the field of neurology, as icobrain aria is 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝗺𝗽𝘂𝘁𝗲𝗿-𝗮𝗶𝗱𝗲𝗱 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 (𝗖𝗔𝗗𝗲) 𝗮𝗻𝗱 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 (𝗖𝗔𝗗𝘅) 𝗱𝗲𝘃𝗶𝗰𝗲 cleared by the FDA! I am so proud of our icometrix team and all our collaborators, partners, and supporters. We are impacting care. We are impacting safety. We are impacting people’s lives. 🧠 Please find some of my thoughts in the article below 👇. The importance of this breakthrough is also summarized in the press release, which can be found in the comments: 👉 Prof. Stephen Salloway: “Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer’s disease but they are associated with a risk of brain swelling and hemorrhage called ARIA. New standardized tools are needed, such as icobrain aria, to assist radiologists and treating clinicians in detecting and managing ARIA to optimize patient safety. I am excited that icobrain aria has received FDA approval, clearing the way for wider use in clinical practice.” 👉 Prof. Jeffrey Cummings: “icobrain aria was thoroughly evaluated in large reader studies. It was demonstrated that the assistance of AI significantly improved radiologists’ ability to detect and classify ARIA, boosting both diagnostic sensitivity and accuracy, and adding a critical safety option for patients undergoing amyloid-targeting therapies.” 👉 Mr. George Vradenburg: “For families facing Alzheimer’s disease, the new disease-modifying therapies have brought renewed hope. But to help as many people as possible, we do need to standardize the care pathways and make sure we have access to cognitive tests, blood biomarkers, and imaging exams that can ensure a timely diagnosis and a safe drug prescription. Thanks to the FDA clearance of icobrain aria, Alzheimer’s therapies are more accessible and safer for patients, as it provides clinicians with the tools they need to make informed, effective treatment decisions.” Biogen Eli Lilly and Company Eisai US Eisai Co., Ltd. Eisai EMEA Roche Novartis beMedTech Alzheimer's Association® Alzheimer's Society American Society of Neuroradiology American Society of Functional Neuroradiology Radiological Society of North America (RSNA) American Academy of Neurology Alzheimer's Drug Discovery Foundation #Alzheimers #ARIA #lecanemab #leqembi #donanemab #kisunla #aduhelm #aducanumab #artificialintelligence #AI #MRI #dementia #neuroradiology #neuroimaging #radiology #neurology #RSNA24
-
Forestay Capital hat dies direkt geteilt
🌟 Introducing Our Esteemed Judge: David Ephrati! 🌟 We are delighted to announce that David Ephrati, Associate at Forestay Capital, will be joining us as a judge for Unicorn Pitches Geneva on November 28th. About David: David is an experienced investment professional at Forestay Capital, a leading European tech-focused venture capital firm based in Geneva. With a strong background in technology investments and strategic growth initiatives, David brings valuable insight into the evolving startup landscape. David's sharp analytical skills will add significant value to our judging panel, providing startups with constructive feedback and valuable connections. Join us as David and other top-tier judges evaluate 10 pioneering startups, share their perspectives on market trends, and select the winner who will move on to the Unicorn CUP in San Francisco. 👉 Event Details: 📅 Date: November 28th, 6 PM 📍 Venue: Hôtel Royal (Rue de Lausanne 41-43, 1201 Genève - Suisse) 💼 Topic: Unicorn Pitches Geneva - Industry-agnostic 🎟️ Secure your spot now: https://lnkd.in/dfMrPcVq We’re excited to have David Ephrati on board and can’t wait for the insights he will share! Don’t miss out on this unique opportunity to witness groundbreaking innovation and network with industry leaders. #UnicornPitches #Geneva #DavidEphrati #ForestayCapital #StartupInnovation #VentureCapital #Entrepreneurship
-
-
Forestay Capital hat dies direkt geteilt
Hello Helsinki!📍Join Nicolas Slotine, Jannat Rajan & Jonas Jeandupeux next week at Slush 2024!
-
-
Congratulations to Neural Concept on this incredible recognition! 🏆 We can't wait to see what you accomplish next! 🌟
🚀 🏆 We're thrilled to announce that Neural Concept has won Scaleup of the Year and Armilar Disruptor of the Year at The Europas, the premier awards for Europe’s hottest tech startups! A huge thank you to The Europas team for this recognition—it's a testament to the hard work, innovation, and passion driving our team forward. We’re proud to be shaping the future of AI-driven engineering and pushing boundaries in the industry. ✨Here’s to many more milestones on our journey! ✨ 🔗 Learn more: https://lnkd.in/d6BWxdVi #TheEuropas #AwardWinning #AI #NeuralConcept #engineeringintelligence
-
-
Hello Helsinki!📍Join Nicolas Slotine, Jannat Rajan & Jonas Jeandupeux next week at Slush 2024!
-
-
📍 Last Tuesday, we hosted the first edition of our Enterprise AI Breakfast Series at our London office, kicking off with AI in Healthcare! 🗣️ Our panel included industry experts Bijoy Sagar, Executive VP and Chief Information Technology and Digital Transformation Officer at Bayer and Wim Van Hecke, co-founder and CEO at icometrix, and was moderated by our Founder & Managing Partner, Frederic Wohlwend. The conversation delved into challenges and opportunities for AI in healthcare, from diagnostics advancements to personalised treatments powered by AI. A huge thank you to everyone who joined us for this inaugural session. We’re looking forward to hosting more of these thought-provoking events in 2025, so stay tuned for what’s next! 🚀
-
-
October updates from our portfolio: 📍 Neural Concept opens New York office https://lnkd.in/eb579P-Z 🧠 icometrix partners with SEQSTER to advance neurological care https://lnkd.in/eVFr7KJ4 📻 Wasabi Technologies partners on first official naming rights for broadcast studio at TD Garden https://lnkd.in/e38bXr_P 🏆 vcita wins 'Best2SMB Offering' by the B2SMB Institute, beating out big competition! https://lnkd.in/e7T-7jYb
-